Abman, S. H. Pulmonary hypertension: The hidden danger for newborns. Neonatology 118, 211–217 (2021).
Puthiyachirakkal, M. & Mhanna, M. J. Pathophysiology, management, and outcome of persistent pulmonary hypertension of the newborn: A clinical review. Front. Pediatr. 1, 23 (2013).
Eriksen, V., Nielsen, L. H., Klokker, M. & Greisen, G. Follow-up of 5- to 11-year-old children treated for persistent pulmonary hypertension of the newborn. Acta Paediatr. (Oslo, Norway : 1992) 98, 304–309 (2009).
Mat-Bah, M. N. et al. Survival and associated risk factors for mortality among infants with persistent pulmonary hypertension of the newborn in Malaysia. J. Perinatol. 41, 786–793 (2021).
Steurer, M. A. et al. Persistent pulmonary hypertension of the newborn in late preterm and term infants in California. Pediatrics 139, 1 (2017).
Arjaans, S. et al. Identification of gaps in the current knowledge on pulmonary hypertension in extremely preterm infants: A systematic review and meta-analysis. Paediatr. Perinat. Epidemiol. 32, 258–267 (2018).
Rosenzweig, E. B. et al. Paediatric pulmonary arterial hypertension: Updates on definition, classification, diagnostics and management. Eur. Respir. J. 53, 2569 (2019).
Kim, Y. J., Shin, S. H., Park, H. W., Kim, E.-K. & Kim, H.-S. Risk factors of early pulmonary hypertension and its clinical outcomes in preterm infants: A systematic review and meta-analysis. Sci. Rep. 12, 14186 (2022).
Hansmann, G. et al. Pulmonary hypertension in bronchopulmonary dysplasia. Pediatr. Res. 89, 446–455 (2021).
Kaluarachchi, D. C., Woo, K. M. & Colaizy, T. T. Role of early pulmonary hypertension as a risk factor for late pulmonary hypertension in extremely preterm infants. Am. J. Perinatol. 35, 120–126 (2018).
Bhat, R., Salas, A. A., Foster, C., Carlo, W. A. & Ambalavanan, N. Prospective analysis of pulmonary hypertension in extremely low birth weight infants. Pediatrics 129, e682–e689 (2012).
Lakshminrusimha, S., Mathew, B. & Leach, C. L. Pharmacologic strategies in neonatal pulmonary hypertension other than nitric oxide. Semin. Perinatol. 40, 160–173 (2016).
Pierce, C. M. et al. Efficacy and safety of IV sildenafil in the treatment of newborn infants with, or at risk of, persistent pulmonary hypertension of the newborn (PPHN): A multicenter, randomized placebo-controlled trial. J. Pediatr. 237, 154-161.e3 (2021).
Chetan, C. et al. Oral versus intravenous sildenafil for pulmonary hypertension in neonates: A randomized trial. BMC Pediatr. 22, 311 (2022).
Sharma, C. et al. Continuous and intermittent administration of intravenous sildenafil in critically ill infants with pulmonary hypertension. Pediatr. Pulmonol. 56, 2973–2978 (2021).
Kelly, L. E., Ohlsson, A. & Shah, P. S. Sildenafil for pulmonary hypertension in neonates. Cochrane Database Syst. Rev. https://doi.org/10.1002/14651858.CD005494.pub4 (2017).
Trottier-Boucher, M. N. et al. Sildenafil for the treatment of pulmonary arterial hypertension in infants with bronchopulmonary dysplasia. Pediatr. Cardiol. 36, 1255–1260 (2015).
Cohen, J. L., Nees, S. N., Valencia, G. A., Rosenzweig, E. B. & Krishnan, U. S. Sildenafil use in children with pulmonary hypertension. J. Pediatr. 205, 29-34.e1 (2019).
Kipfmueller, F. et al. Continuous intravenous sildenafil as an early treatment in neonates with congenital diaphragmatic hernia. Pediatr. Pulmonol. 53, 452–460 (2018).
Thandaveshwara, D., Chandrashekar-Reddy, A. H., Gopalakrishna, M. V. & Doreswamy, S. M. Saturation oxygenation pressure index: A non-invasive bedside measure for severity of respiratory disease in neonates on CPAP. Eur. J. Pediatr. 180, 1287–1292 (2021).
Gaies, M. G. et al. Vasoactive-inotropic score is associated with outcome after infant cardiac surgery: An analysis from the Pediatric Cardiac Critical Care Consortium and virtual PICU system registries. Pediatr. Crit. Care Med. 15, 529–537 (2014).
Pels, A. et al. Neonatal pulmonary hypertension after severe early-onset fetal growth restriction: Post hoc reflections on the Dutch STRIDER study. Eur. J. Pediatr. 181, 1709–1718 (2022).
Steinhorn, R. H. et al. Intravenous sildenafil in the treatment of neonates with persistent pulmonary hypertension. J. Pediatr. 155, 841-847.e1 (2009).
Cochius-den-Otter, S. C. M. et al. Pharmacokinetic modeling of intravenous sildenafil in newborns with congenital diaphragmatic hernia. Eur. J. Clin. Pharmacol. 76, 219–227 (2020).
Maratta, C. et al. Extracorporeal life support organization (ELSO): 2020 pediatric respiratory ELSO guideline. ASAIO J. (Am. Soc. Artif. Intern. Organs : 1992) 66, 975–979 (2020).
Snoek, K. G. et al. Standardized postnatal management of infants with congenital diaphragmatic hernia in Europe: The CDH EURO Consortium Consensus—2015 Update. Neonatology 110, 66–74 (2016).
Mertens, L. et al. Targeted neonatal echocardiography in the neonatal intensive care unit: Practice guidelines and recommendations for training. Eur. J. Echocardiogr. 12, 715–736 (2011).
Tissot, C., Singh, Y. & Sekarski, N. Echocardiographic evaluation of ventricular function-for the neonatologist and pediatric intensivist. Front. Pediatr. 6, 79 (2018).
Laudy, J. A. & Wladimiroff, J. W. The fetal lung 2: Pulmonary hypoplasia. Ultrasound Obstetr. Gynecol. 16, 482–494 (2000).
Nees, S. N., Rosenzweig, E. B., Cohen, J. L., Valencia-Villeda, G. A. & Krishnan, U. S. Targeted therapy for pulmonary hypertension in premature infants. Children (Basel, Switzerl.) 7, 97 (2020).
Tan, K., Krishnamurthy, M. B., O’Heney, J. L., Paul, E. & Sehgal, A. Sildenafil therapy in bronchopulmonary dysplasia-associated pulmonary hypertension: A retrospective study of efficacy and safety. Eur. J. Pediatr. 174, 1109–1115 (2015).
Schneider, S. et al. Safety of sildenafil in premature infants with severe bronchopulmonary dysplasia (SILDI-SAFE): A multicenter, randomized, placebo-controlled, sequential dose-escalating, double-masked, safety study. BMC Pediatr. 20, 559 (2020).
Mirza, H. et al. Natural history of postnatal cardiopulmonary adaptation in infants born extremely preterm and risk for death or bronchopulmonary dysplasia. J. Pediatr. 198, 187-193.e1 (2018).
Gan, C.T.-J. et al. Right ventricular diastolic dysfunction and the acute effects of sildenafil in pulmonary hypertension patients. Chest 132, 11–17 (2007).
Borgdorff, M. A. et al. Sildenafil treatment in established right ventricular dysfunction improves diastolic function and attenuates interstitial fibrosis independent from afterload. Am. J. Physiol. Heart Circul. Physiol. 307, H361–H369 (2014).
Corrado, P. A., Barton, G. P., Francois, C. J., Wieben, O. & Goss, K. N. Sildenafil administration improves right ventricular function on 4D flow MRI in young adults born premature. Am. J. Physiol. Heart Circul. Physiol. 320, 295–304 (2021).
Monzo, L. et al. Acute unloading effects of sildenafil enhance right ventricular-pulmonary artery coupling in heart failure. J. Cardiac Fail. 27, 224–232 (2021).
Imai, Y., Kariya, T., Iwakiri, M., Yamada, Y. & Takimoto, E. Sildenafil ameliorates right ventricular early molecular derangement during left ventricular pressure overload. PLoS ONE 13, e0195528 (2018).
Guazzi, M., Vicenzi, M., Arena, R. & Guazzi, M. D. PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: Results of a 1-year, prospective, randomized, placebo-controlled study. Circ. Heart Fail. 4, 8–17 (2011).